Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2025-12-26 @ 2:46 AM
NCT ID:
NCT00306202
Description:
None
Frequency Threshold:
5
Time Frame:
From first dose to 100 days post last dose
Study:
NCT00306202
Study Brief:
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
Event Groups(If Any):
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose | Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained. | None | None | 8 | 17 | 16 | 17 | View |
| Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose | Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained. | None | None | 14 | 17 | 16 | 17 | View |
| Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose | Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained. | None | None | 22 | 24 | 24 | 24 | View |
Serious Events(If Any):
Serious Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Febrile neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 22.1 | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 22.1 | View |
| Palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 22.1 | View |
| Abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Ascites | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Colitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Enterocolitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Ileus | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Lower gastrointestinal haemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Pancreatitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Stomatitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Upper gastrointestinal haemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Multiple organ dysfunction syndrome | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Performance status decreased | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Anaphylactic shock | SYSTEMATIC_ASSESSMENT | Immune system disorders | 22.1 | View |
| Graft versus host disease | SYSTEMATIC_ASSESSMENT | Immune system disorders | 22.1 | View |
| Hypersensitivity | SYSTEMATIC_ASSESSMENT | Immune system disorders | 22.1 | View |
| Anal infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Bronchitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Cellulitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Device related infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Escherichia sepsis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Febrile infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Gastroenteritis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Sepsis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Septic shock | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Varicella zoster virus infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Ammonia increased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Hepatic enzyme increased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| White blood cell count increased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Decreased appetite | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Hypocalcaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Hypomagnesaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Tumour lysis syndrome | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Bone pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Musculoskeletal pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Acute myeloid leukaemia | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 22.1 | View |
| Malignant neoplasm progression | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 22.1 | View |
| Coma | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Facial nerve disorder | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Syncope | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Thrombosis in device | SYSTEMATIC_ASSESSMENT | Product Issues | 22.1 | View |
| Depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Renal failure | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 22.1 | View |
| Pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Pneumonitis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Respiratory failure | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Exfoliative rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Rash macular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Urticaria | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 22.1 | View |
Other Events(If Any):
Other Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 22.1 | View |
| Pancytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 22.1 | View |
| Splenomegaly | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 22.1 | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 22.1 | View |
| Palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 22.1 | View |
| Ear discomfort | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | 22.1 | View |
| Ear pain | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | 22.1 | View |
| Joint injury | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Haemoglobin decreased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Tumour lysis syndrome | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Skin papilloma | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 22.1 | View |
| Middle ear effusion | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | 22.1 | View |
| Chalazion | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Dacryoadenitis acquired | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Dry eye | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Erythema of eyelid | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Eye discharge | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Eye pain | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Eye pruritus | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Eye swelling | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Eyelid oedema | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Eyelid ptosis | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Orbital oedema | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Periorbital oedema | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Swelling of eyelid | SYSTEMATIC_ASSESSMENT | Eye disorders | 22.1 | View |
| Abdominal discomfort | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Abdominal distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Abdominal pain lower | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Abdominal pain upper | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Aphthous ulcer | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Colitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Dental caries | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Dyspepsia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Flatulence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Gingival bleeding | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Irritable bowel syndrome | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Mouth ulceration | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Oral mucosal blistering | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Oral pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Periodontal disease | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Tongue disorder | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Tongue ulceration | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Tooth loss | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Toothache | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 22.1 | View |
| Asthenia | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Catheter site erythema | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Catheter site haemorrhage | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Catheter site pain | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Chest pain | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Chills | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Face oedema | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Influenza like illness | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Injection site pain | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Injection site reaction | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Malaise | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Mucosal inflammation | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Oedema | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Oedema peripheral | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Peripheral swelling | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Swelling | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Swelling face | SYSTEMATIC_ASSESSMENT | General disorders | 22.1 | View |
| Hepatomegaly | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 22.1 | View |
| Hepatotoxicity | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 22.1 | View |
| Hyperbilirubinaemia | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 22.1 | View |
| Drug hypersensitivity | SYSTEMATIC_ASSESSMENT | Immune system disorders | 22.1 | View |
| Hypersensitivity | SYSTEMATIC_ASSESSMENT | Immune system disorders | 22.1 | View |
| Conjunctivitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Conjunctivitis bacterial | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Cystitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Device related infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Epididymitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Eye infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Folliculitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Fungal skin infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Gastrointestinal infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Herpes simplex | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Herpes zoster | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Lice infestation | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Lower respiratory tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Molluscum contagiosum | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Nasopharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Oral fungal infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Oral herpes | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Otitis externa | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Otitis media | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Pharyngitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Rhinitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Sinusitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Skin infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Tinea cruris | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Upper respiratory tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Varicella | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Viral infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Viral rhinitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Viral upper respiratory tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 22.1 | View |
| Arthropod bite | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Clavicle fracture | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Contusion | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Head injury | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Ligament sprain | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Mouth injury | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Post lumbar puncture syndrome | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Post-traumatic pain | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Skin abrasion | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Skin laceration | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Sunburn | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Wound | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 22.1 | View |
| Body temperature | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Heart rate increased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Hepatic enzyme increased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Weight decreased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Weight increased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| White blood cell count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 22.1 | View |
| Decreased appetite | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Hyperglycaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Hypokalaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 22.1 | View |
| Aneurysmal bone cyst | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Bone pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Epiphyses delayed fusion | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Growth retardation | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Hypermobility syndrome | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Muscle spasms | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Muscle tightness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Muscular weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Musculoskeletal chest pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Musculoskeletal disorder | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Musculoskeletal pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Neck pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Osteoporosis | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Pain in extremity | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 22.1 | View |
| Chloroma | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 22.1 | View |
| Disturbance in attention | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Facial paralysis | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Intracranial pressure increased | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Neuralgia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Post-traumatic headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 22.1 | View |
| Agitation | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Anxiety | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Depressed mood | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Enuresis | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Sleep disorder | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Suicidal ideation | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 22.1 | View |
| Ovarian failure | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | 22.1 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Dry throat | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Epistaxis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Nasal congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Oropharyngeal pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Pulmonary oedema | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Rhinorrhoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Wheezing | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 22.1 | View |
| Acne | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Alopecia | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Dermatitis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Dermatitis acneiform | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Dermatitis contact | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Dry skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Erythema | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Hair colour changes | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Hyperhidrosis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Miliaria | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Nail disorder | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Night sweats | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Petechiae | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Pigmentation disorder | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Rash macular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Skin disorder | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Urticaria | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 22.1 | View |
| Flushing | SYSTEMATIC_ASSESSMENT | Vascular disorders | 22.1 | View |
| Hot flush | SYSTEMATIC_ASSESSMENT | Vascular disorders | 22.1 | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 22.1 | View |
| Thrombosis | SYSTEMATIC_ASSESSMENT | Vascular disorders | 22.1 | View |